Delphyr key facts
as of Oct 2026- Developer of an artificial intelligence-driven medical data platform designed to enable patient-level data analytics for clinicians.
- Delphyr is valued at approximately $2.7M as of Oct 2026 (last reported valuation).
- It has raised $2.6M; the latest was Early Stage VC ($2.1M) in Mar 2026.
- Notable investors include Innovatiefonds Noord-Holland, Thomas Wolf, Clément Delangue, Julien Chaumond, LENOS Equity — 6 tracked in total.
- Status: Privately Held (backing).
Delphyr's last reported valuation, Jun 2024. Nothing priced has surfaced since.
- ·Watch Delphyr: the Monday email on marks, rounds and moves
Delphyr funding rounds
No funding rounds for Delphyr are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Delphyr valuation
Delphyr's last reported valuation was $2.7 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.
Delphyr investors
6 investors are on record for Delphyr, including Innovatiefonds Noord-Holland, Thomas Wolf, Clément Delangue and Julien Chaumond.
About Delphyr
Developer of an artificial intelligence-driven medical data platform designed to enable patient-level data analytics for clinicians. The company's platform offers an intuitive interface, real-time access to patient information, and integration with existing healthcare systems, enabling healthcare professionals to save time, improve patient outcomes, and reduce hospital costs.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2023
- Employees
- 9
- Website
- delphyr.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.